Establishment Labs (NASDAQ:ESTA) Sets New 52-Week High – Time to Buy?

Shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) hit a new 52-week high during mid-day trading on Monday . The stock traded as high as $90.50 and last traded at $90.4970, with a volume of 140799 shares trading hands. The stock had previously closed at $89.25.

Wall Street Analysts Forecast Growth

Several research firms recently commented on ESTA. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Establishment Labs in a report on Wednesday, June 24th. TD Cowen restated a “buy” rating on shares of Establishment Labs in a research report on Monday, June 8th. Citigroup reaffirmed a “neutral” rating on shares of Establishment Labs in a research note on Wednesday. BTIG Research boosted their target price on shares of Establishment Labs from $88.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, May 7th. Finally, Wall Street Zen downgraded shares of Establishment Labs from a “buy” rating to a “hold” rating in a report on Saturday, March 28th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $87.14.

Establishment Labs Stock Performance

The company has a market capitalization of $2.60 billion, a price-to-earnings ratio of -59.33 and a beta of 1.06. The firm has a fifty day simple moving average of $76.87 and a 200 day simple moving average of $71.15. The company has a debt-to-equity ratio of 16.82, a current ratio of 2.96 and a quick ratio of 1.91.

Establishment Labs (NASDAQ:ESTA) last announced its earnings results on Thursday, May 7th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.10). Establishment Labs had a negative net margin of 19.05% and a negative return on equity of 218.77%. The business had revenue of $59.88 million for the quarter, compared to analysts’ expectations of $57.40 million. During the same quarter last year, the business earned ($0.70) EPS. The company’s quarterly revenue was up 44.7% on a year-over-year basis. On average, analysts anticipate that Establishment Labs Holdings Inc. will post -1.07 earnings per share for the current fiscal year.

Insider Transactions at Establishment Labs

In other news, Director Quiros Juan Jose Chacon sold 105,000 shares of Establishment Labs stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $75.42, for a total value of $7,919,100.00. Following the sale, the director owned 927,504 shares in the company, valued at $69,952,351.68. This trade represents a 10.17% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold 292,500 shares of company stock worth $20,591,021 over the last quarter. Company insiders own 9.99% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of ESTA. KBC Group NV acquired a new stake in Establishment Labs in the 1st quarter worth about $28,000. Kestra Advisory Services LLC purchased a new position in shares of Establishment Labs in the fourth quarter valued at approximately $47,000. Quarry LP purchased a new position in shares of Establishment Labs in the third quarter valued at approximately $34,000. MV Capital Management Inc. acquired a new stake in shares of Establishment Labs in the fourth quarter worth approximately $146,000. Finally, Osaic Holdings Inc. boosted its stake in shares of Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the last quarter. 72.91% of the stock is owned by hedge funds and other institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.